ReviewLancet regional health. Americas2025
Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably.
Review in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Pricing of innovative medicines and advanced therapies worldwide: an scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Optimizing HIV Spending Among Key Populations in Five Latin American and Caribbean Countries: A Mathematical Modelling Study.Journal of the International AIDS Society · 2026Article
- Awareness, knowledge, perception and behavioral risk predictors of acceptability of long-acting injectable lenacapavir HIV pre-exposure prophylaxis in Ghana: a cross-sectional study.AIDS research and therapy · 2026Article
- Challenges and Opportunities for Improved Tuberculosis and HIV Prevention in South America.Open forum infectious diseases · 2026Review
- Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic.Microbial biotechnology · 2026Review
- HIV response financing challenges in Sub-Saharan Africa: barriers to achieving the 95-95-95 UNAIDS targets.Frontiers in public health · 2025Review
- Implementation of Daily Oral PrEP at HIV/AIDS Service Organizations in Lima, Peru: Early Findings From the PrEP PERU Demonstration Study.Journal of the International Association of Providers of AIDS CareArticle
- Lenacapavir for HIV Prevention in Africa: Opportunities, Barriers, and Policy Priorities.Journal of the International Association of Providers of AIDS CareReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lenacapavir, a first in class long-acting capsid inhibitor has near 100% efficacy in preventing HIV. As such, it has the potential to curb the rising HIV incidence in Latin America, a region with stark intra- and inter-country PrEP uptake disparities. In this viewpoint, we summarize the current efforts to scale up lenacapavir access globally and the necessary steps to include Latin America in these endeavours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.